NCT03767829View on ClinicalTrials.gov

A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 5, 2018

Primary Completion Date

June 25, 2020

Study Completion Date

June 25, 2020

Conditions
ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
Interventions
DRUG

ALN-AAT02

ALN-AAT02 will be administered subcutaneously (SC) at dose levels planned for Part A.

DRUG

Placebo

Sterile normal saline (0.9% NaCl) matching volume of ALN-AAT02 doses will be administered SC.

DRUG

ALN-AAT02

ALN-AAT02 will be administered subcutaneously (SC). Part B dose levels to be determined upon review of data from Part A.

Trial Locations (1)

Unknown

Clinical Trial Site, London

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY